PDCD1 and lung carcinoma: Although the incidence rate of immune-mediated pneumonitis is less than 5% in lung cancer patients receiving anti-PD-1/PD-L1 immunotherapy, this adverse event is a major morbidity that can lead to permanent discontinuation of immunotherapy and even mortality in severe cases [40,41].